Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Inside the Senate bill

Inside the Senate bill

Summary BIO arguments
Would move drugs now covered under Part B(administered "incident" to a physician's service) into the new Medicare prescription drug benefit, which would require rebates Biotech drugs disproportionately affected because they are administered in large part through transfusion or injection "incident" to a physician's service.
Creates additional tax for biotech drugs already on market.

Read the full 607 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE